1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer

Enfortumab Progresses As US Accelerated Approval Eyed In Urothelial Cancer

 
• By Ian Haydock

Astellas and Seattle Genetics now expect key top-line data on their antibody-drug conjugate in urothelial cancer in the first half of next year, as pivotal trials in support of a planned US accelerated approval progress.

Cancer cells on scientific background.3d illustration
ENFORTUMAB VEDOTIN MOVES AHEAD IN UROTHELIAL CANCER • Source: Shutterstock

Following encouraging Phase I results, Astellas Pharma Inc. and Seattle Genetics Inc. now expect key top-line data from a pivotal Phase II trial with their antibody-drug conjugate (ADC) enfortumab vedotin in the first half of next year, which will be used to support a planned US accelerated approval filing for later-line use in urothelial cancer.

The companies said enrollment had now been completed in the EV-201 study in patients with locally advanced or metastatic disease...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

More from Therapy Areas

Spyre Takes Aim At Roche And J&J In Inflammatory Diseases

 
• By Andrew McConaghie

The US firm was already looking to compete in ulcerative colitis, but now expands its ambitions by moving into rheumatoid arthritis as well.

Draig Is All Fired Up To Transform Neuropsychiatric Field

 
• By Kevin Grogan

Wales-based group launches with $140m series A.

Immuneering Could Partner Atebimetinib Or Go It Alone After Phase IIa Success

 
• By Alaric DeArment

CEO Ben Zeskind said all options are on the table after atebimetinib showed impressive results in pancreatic cancer.